CVS Health (CVS) closed at $79.12 in the latest trading session, marking a +1.38% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.32%. Meanwhile, the ...

Forget the dupes. You can currently score real-deal Creed Aventus at drugstore prices Costco can't even match. Really.

CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

CVS Health’s stock rose more than 2% on Tuesday after the company boosted its revenue and profit guidance for the year and detailed its full-year expectations for 2026. The healthcare giant, which ...

CVS Health’s (NYSE: CVS) latest results affirm several points: their sales and adjusted profits remain stable, and they are adjusting their forecasts upward. Nonetheless, the quality of their profits ...

CVS Health Corporation (NYSE:CVS) is among the cheap healthcare stocks to buy heading into 2026. On December 4, Bernstein SocGen Group lifted the price target on CVS Health Corporation (NYSE:CVS) to ...

CVS Health has put out new guidance for 2025, saying it now expects higher revenue than previously outlined. CVS Health's stock rose more than 2% on Tuesday after the company boosted its revenue and ...

CVS Health is positioned for continued outperformance, with a strong turnaround driving industry-leading results and a reiterated "Buy" rating. CVS's Q3 showed 7.8% revenue growth, 47% adjusted EPS ...

CVS Health Corp. raised its full-year profit forecast and said earnings would rise in 2026, a sign of hope as it navigates a turbulent retail environment and government scrutiny across the health care ...

CVS is a strong buy now, with rising earnings, solid dividends, and steady growth prospects despite industry challenges. Read here for more analysis.

ROUND ROCK, Texas — A man is in custody after police say he barricaded himself inside a CVS Pharmacy early Tuesday morning in Round Rock. According to the Round Rock Police Department (RRPD), officers ...

NEW YORK, Dec 2 (Reuters) - CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, Medicaid ...